Kazano FDA Approval History
FDA Approved: Yes (First approved January 25, 2013)
Brand name: Kazano
Generic name: alogliptin and metformin
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: Diabetes, Type 2
Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.
Development Timeline for Kazano
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.